Top

Osteoporosis International

Published in:

01-06-2009 | Original Article

Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study

Authors: R. Nuti, P. Siviero, S. Maggi, G. Guglielmi, C. Caffarelli, G. Crepaldi, S. Gonnelli

Published in: Osteoporosis International | Issue 6/2009

Abstract

Summary

This study aimed to evaluate the prevalence of vertebral fractures to investigate the determinants of vertebral fracture risk in patients with COPD. The risk of vertebral fractures is strictly related to the severity of the disease. The use of glucocorticoids and the presence of low values of quantitative ultrasound (QUS) may represent additional risk factors.

Introduction

Chronic obstructive pulmonary disease (COPD) appears to be associated with osteoporosis. Our study aimed to evaluate the prevalence of vertebral fractures and to investigate the main determinants of vertebral fracture risk in patients with COPD.

Methods

In 3,030 ambulatory COPD patients (1,778 men and 1,262 women) aged 50 years or over, we evaluated: COPD severity, presence of vertebral fractures on lateral chest X-ray and bone status by using a quantitative ultrasound device.

Results

In men there was a strong association between COPD severity and fractures (p < 0.001), conversely in women the association between COPD severity and fractures was at limit (p = 0.049). In men, but not in women, glucocorticoid treatment was significantly associated with vertebral fractures. The patients with high or moderate risk of osteoporosis presented an increased risk of vertebral fracture (OR 2.71; 95% CI 2.04–3.60 and OR 1.54; 95% CI 1.26–1.88, respectively). Logistic regression analysis showed that COPD severity and glucocorticoid treatment, both inhaled and oral, were associated with increased risk of vertebral fractures.

Conclusion

In COPD patients the risk of vertebral fractures is strictly related to the severity of the disease. The use of glucocorticoids and reduced QUS at calcaneous may represent additional risk factors.

Rabe KF, Hurd S, Anzueto A et al (2007) Global initiative for chronic obstructive lung disease global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 15(176):532–555CrossRef

Wouters EF, Celis MP, Breyer MK et al (2007) Co-morbid manifestations in COPD. Respir Med: COPD update 3:135–151CrossRef

Biskobing DM (2002) COPD and osteoporosis. Chest 121:609–620PubMedCrossRef

Ionescu AA, Schoon E (2003) Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J 22(Suppl 46):64s–75sCrossRef

Gluck O, Colice G (2004) Recognizing and treating glucocorticoid-induced osteoporosis in patients with pulmonary diseases. Chest 125:1859–1876PubMedCrossRef

Praet JP, Peretz A, Rozenberg S et al (1992) Risk of osteoporosis in men with chronic bronchitis. Osteoporos Int 2:257–261PubMedCrossRef

Iqbal F, Michaelson J, Thaler L et al (1999) Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 116:1616–1624PubMedCrossRef

Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRef

The Lung Health Study Research Group (2000) Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343:1902–1909CrossRef

10.

Pauwels RA, Löfdahl CG, Laitinen LA et al (1999) Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med 340:1948–1953PubMedCrossRef

11.

Sosa M, Saavedra P, Valero C, GIUMO Study Group et al (2006) Inhaled steroids do not decrease bone mineral density but increase risk of fractures: data from the GIUMO Study Group. J Clin Densitom 9:154–158PubMedCrossRef

12.

Kjensli A, Mowinckel P, Ryg MS et al (2007) Low bone mineral density is related to severity of chronic obstructive pulmonary disease. Bone 40:493–497PubMedCrossRef

13.

Vrieze A, de Greef MH, Wijkstra PJ et al (2007) Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int 18:1197–1202PubMedCrossRef

14.

Katsura H, Kida K (2002) A comparison of bone mineral density in elderly female patients with COPD and bronchial asthma. Chest 122:1949–1955PubMedCrossRef

15.

Incalzi RA, Caradonna P, Ranieri P et al (2000) Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir Med 94:1079–1084PubMedCrossRef

16.

Dimai HP, Domej W, Leb G et al (2001) Bone loss in patients with untreated chronic obstructive pulmonary disease is mediated by an increase in bone resorption associated with hypercapnia. J Bone Miner Res 16:2132–2141PubMedCrossRef

17.

Vermeeren MA, Creutzberg EC, Schols AM, on behalf of the COSMIC Study Group et al (2006) Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med 100:1349–1355PubMedCrossRef

18.

Papaioannou A, Parkinson W, Ferko N et al (2003) Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int 14:913–917PubMedCrossRef

19.

Schlaich C, Minne HW, Bruckner T et al (1998) Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int 8:261–267PubMedCrossRef

20.

Kado DM, Browner WS, Palermo L et al (1999) Vertebral fractures and mortality in older women: a prospective study. Study of osteoporotic fractures research group. Arch Intern Med 159:1215–1220PubMedCrossRef

21.

Riancho JA, Gonzalez Macias J, Del Arco C et al (1987) Vertebral compression fractures and mineral metabolism in chronic obstructive lung disease. Thorax 42:962–966PubMedCrossRef

22.

McEvoy CE, Ensrud KE, Bender E et al (1998) Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:704–709PubMed

23.

de Vries F, van Staa TP, Bracke MS et al (2005) Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 25:879–884PubMedCrossRef

24.

Jørgensen NR, Schwarz P, Holme I et al (2007) The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 101:177–185PubMedCrossRef

25.

de Vries F, Bracke M, Leufkens HG et al (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214PubMedCrossRef

26.

Vestergaard P, Rejnmark L, Mosekilde L (2007) Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest 132:1599–1607PubMedCrossRef

27.

Guglielmi G, Stoppino LP, Placentino MG et al. (2007) Reproducibility of a semi-automatic method for 6-point vertebral morphometry in a multi-centre trial. Eur J Radiol. Published online December 8 doi:10.1016/j.ejrad.2007.09.040

28.

Genant HK, Wu CY, van Kuijk C et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148PubMed

29.

Krieg MA, Barkmann R, Gonnelli S et al (2008) Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 11:163–187PubMedCrossRef

30.

O'Neill TW, Felsenberg D, Varlow J et al (1996) The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010–1018PubMedCrossRef

31.

Angeli A, Guglielmi G, Dovio A et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253–259PubMedCrossRef

32.

Lekamwasam S, Trivedi DP, Khaw KT (2002) An association between respiratory function and bone mineral density in women from the general community: a cross sectional study. Osteoporos Int 13:710–715PubMedCrossRef

33.

Bonnet N, Benhamou CL, Brunet-Imbault B et al (2005) Severe bone alterations under beta2 agonist treatments: bone mass, microarchitecture and strength analyses in female rats. Bone 37:622–633PubMedCrossRef

34.

de Vries F, Pouwels S, Bracke M et al (2007) Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 16:612–619PubMedCrossRef

35.

Vestergaard P, Rejnmark L, Mosekilde L et al (2007) Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest 132:1599–607PubMedCrossRef

36.

van Staa TP, Leufkens HG, Cooper C (2001) Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 16:581–588PubMedCrossRef

37.

de Vries F, Pouwels S, Lammers JW et al (2007) Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 261:170–177PubMed

38.

Huopio J, Kröger H, Honkanen R et al (2004) Calcaneal ultrasound predicts early postmenopausal fractures as well as axial BMD. A prospective study of 422 women. Osteoporos Int 15:190–195PubMedCrossRef

Title: Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study
Authors: R. Nuti
P. Siviero
S. Maggi
G. Guglielmi
C. Caffarelli
G. Crepaldi
S. Gonnelli
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 6/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-008-0770-4

At a glance: The STEP trials

Springer Medicine

Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2009

DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass

Bone mineral: update on chemical composition and structure

Ultrastructural characteristics of glucocorticoid-induced osteoporosis

Bone ultrastructure: evolution during osteoporosis and aging

Events

Bone microdamage